Plasmin and matrix metalloproteinases in vascular remodeling

Thrombosis and Haemostasis

Volumn 86, Issue 1, 2001, Pages 324-333

  Lijnen, H R ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Cardiovascular disease; Fibrinolysis; Matrix metalloproteinases; Vascular remodeling

Indexed keywords

ALPHA 2 ANTIPLASMIN; COLLAGENASE 3; DOXYCYCLINE; GELATINASE B; MACROPHAGE ELASTASE; MATRIX METALLOPROTEINASE; PLASMIN; PLASMINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATOR INHIBITOR 2; PROTEINASE INHIBITOR; STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE; UROKINASE RECEPTOR;

ABDOMINAL AORTA ANEURYSM; ALLOGRAFT; ATHEROSCLEROSIS; BLOOD VESSEL INJURY; BLOOD VESSEL WALL; CARDIOVASCULAR DISEASE; CELL MIGRATION; COLLAGEN DEGRADATION; CONFERENCE PAPER; CORONARY ARTERY DISEASE; ELASTOLYSIS; ENZYME DEFICIENCY; EXTRACELLULAR MATRIX; FIBRINOLYSIS; HEART FAILURE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART RUPTURE; HEMODYNAMICS; HUMAN; MACROPHAGE; METABOLIC ACTIVATION; MOLECULAR INTERACTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN STRUCTURE; PROTEIN SYNTHESIS; RESTENOSIS; SMOOTH MUSCLE FIBER;

EID: 0034927107     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1616230     Document Type: Conference Paper

References (123)

1. Review: Clinical aspects of vascular remodeling
2. Development and disease in proteinase-deficient mice: Role of the plasminogen, matrix metalloproteinase and coagulation system
3. Molecular interactions between the plasminogen/plasmin and matrix metalloproteinase systems
4. Ultrasonographic features of uterine blood flow during the first 16 weeks of pregnancy
5. Mechanisms of physiological fibrinolysis
6. Basic and clinical aspects of fibrinolysis and thrombolysis
7. Urokinase and urokinase receptor: A paracrine/autocrine system regulating cell migration and invasiveness
8. The plasminogen activator/plasmin system
9. Pathophysiology of fibrinolysis
10. Matrix metalloproteinases: A review
11. Matrix metalloproteinases
12. Cloning and characterization of human MMP-23, a new matrix metalloproteinase predominantly expressed in reproductive tissues and lacking conserved domains in other family members
13. Furin-dependent intracellular activation of the human stromelysin-3 zymogen
14. A novel matrix metalloproteinase gene (XMMP) endocing vitronectin-like motifs is transiently expressed in Xenopus laevis early embryo development
15. Astacins, serralysins, snake venom and matrix metalloproteinases exhibit identical zinc-binding environments (HEXXHXXGXXH and Met-turn) and topologies and should be grouped into a common family, the 'metzincins'
16. Binding of gelatinases A and B to type-I collagen and other matrix components
17. Matrix metalloproteinases: Structures, evolution, and diversification
18. The C-terminal domain of 72 kDa gelatinase A is not required for catalysis, but is essential for membrane activation and modulates interactions with tissue inhibitors of metalloproteinases
19. Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease
20. Matrilysin-2, a new matrix metalloproteinase expressed in human tumors and showing the minimal domain organization required for secretion, latency, and activity
21. Membrane-type matrix metalloproteinases (MT-MMPs) in tumor metastasis
22. Activation mechanisms of matrix metalloproteinases
23. Tissue inhibitors of metalloproteinases: Evolution, structure and function
24. Matrix metalloproteinase 9 (92-kDa gelatinase/type IV collagenase) from HT1080 human fibrosarcoma cells. Purification and activation of the precursor and enzymic properties
25. Mechanisms of activation of tissue procollagenase by matrix metalloproteinase 3 (stromelysin)
26. Further studies on the activation of procollagenase, the latent precursor of bone collagenase. Effects of lysosomal cathepsin B, plasmin and kallikrein, and spontaneous activation
27. Tissue cooperation in a proteolytic cascade activating human interstitial collagenase
28. Involvement of PA/plasmin system in the processing of proMMP-9 and in the second step of proMMP-2 activation
29. Proteolytic processing of the 72,000 Da type IV collagenase by urokinase plasminogen activation
30. Stromelysin-1 (MMP-3)-independent gelatinase expression and activation in mice
31. Matrix metalloproteinase 3 (stromelysin) activates the precursor of the human matrix mettalloproteinase 9
32. Proteolytic cleavage of urokinase-type plasminogen activator by stromelysin-1 (MMP-3)
33. The matrix metalloproteinase pump-1 catalyzes formation of low molecular weight (pro)urokinase in cultures of normal human kidney cells
34. Generation of an angiostatin-like fragment from plasminogen by stromelysin-1 (MMP-3)
35. Angiostatin-converting enzyme activities of human matrilysin (MMP-7) and gelatinase B/type IV collagenase (MMP-9)
36. Macrophage-derived metalloelastase in responsible for the generation of angiostatin in Lewis lung carcinoma
37. Modulation of cell-associated plasminogen activation by stromelysin-1 (MMP-3)
38. Degradation of cross-linked fibrin by matrix metalloproteinase 3 (stromelysin 1): Hydrolysis of the gamma Gly 404 - Ala 405 peptide bond
39. Characterization of stromelysin-1 (MMP-3), matrilysin (MMP-7), and membrane type 1 matrix metalloproteinase (MT1-MMP) derived fibrin(ogen) fragments D-dimer and D-like monomer: NH2-terminal sequences of late-stage digest fragments
40. Plasminogen/plasmin and matrix metalloproteinase system function in mice with targeted inactivation of stromelysin-3 (MMP-11)
41. The role of endothelium in cardiovascular homeostasis and diseases
42. Atherosclerosis - An inflammatory diasease
43. Transgenic mouse models in angiogenesis and cardiovascular disease
44. Identification of 92-kD gelatinase in human coronary atherosclerotic lesions. Association of active enzyme synthesis with unstable angina
45. Macrophages and atherosclerotic plaque stability
46. On the role of coagulation and fibrinolysis and atherosclerosis
47. Fibrinolysis and atherosclerosis: An update
48. Increased by type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries
49. Cellular localization of matrix metalloproteinase in the abdominal aortic aneurysm wall
50. Activated forms of MMP2 and MMP9 in abdominal aortic aneurysms
51. Expression of fibrinolytic genes in atherosclerotic abdominal aortic aneurysm wall. A possible mechanism for aneurysm expansion
52. Plasminogen activator expression in human atherosclerotic lesions
53. Macrophage foam cells from experimental atheroma constitutively produce matrix-degrading proteinases
54. Localization of stromelysin gene expression in artherosclerotic plaques by in situ hybridization
55. Enhanced expression of vascular matrix metalloproteinases induced in vitro by cytokines and in regions of human atherosclerotic lesions
56. Expression of stromelysin-3 in atherosclerotic lesions: Regulation via CD40-CD40 ligand signaling in vitro and in vivo
57. Membrane type 1 matrix metalloproteinase expression in human atherosclerotic plaques: Evidence for activation by proinflammatory mediators
58. Coexpression of cyclooxygenase-2 and matrix metalloproteinases in human aortic atherosclerotic lesions
59. Oxidized low-density lipoprotein regulates matrix metalloproteinase-9 and its tissue inhibitor in human monocyte-derived macrophages
60. Interleukin-8 mediates downregulation of tissue inhibitor of metalloproteinase-1 expression in cholesterol-loaded human macrohages: Relevance to stability of atherosclerotic plaque
61. Expression of tissue inhibitor of metalloproteinases-3 in human atheroma and regulation in lesion-associated cells: A potential protective mechanism in plaque stability
62. Activation of matrix-degrading metalloproteinases by mast cell proteases in atherosclerotic plaques
63. The ACAT inhibitor avasimibe reduces macrophages and matrix metalloproteinase expression in atherosclerotic lesions of hypercholemic rabbits
64. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells
65. Urokinase-generated plasmin is a candidate activator of matrix metalloproteinases during atherosclerotic aneurysm formation
66. Persistence of atherosclerotic plaque and reduced aneurysm formation in mice with stromelysin-1 (MMP-3) gene inactivation
67. Adenovirus-mediated ovexpression of tissue inhibitor of metalloproteinase-1 reduces atherosclerotic lesions in apolipoprotein E-deficient mice
68. Local overexpression of TIMP-1 prevents aortic aneurysm degeneration and rupture in a rat model
69. Matrix metalloproteinases and cardiovascular disease
70. Matrix metalloproteinases and coronary artery disease: A novel therapeutic target
71. Cytokine-stimulated human vascular smooth muscle cells synthesize a complement of enzymes required for extracellular matrix digestion
72. Matrilysin is expressed by lipid-laden macrophages at sites of potential rupture in atherosclerotic lesions and localizes to areas of versican deposition, a proteoglycan substrate for the enzyme
73. Demonstration of interstitial collagenase in abdominal aortic aneurysm disease
74. Reduced transplant arteriosclerosis in plasminogen deficient mice
75. Smooth muscle cells express urokinase during mitogenesis and tissue-type plasminogen activator during migration in injured rat carotid artery
76. The role of plasminogen activation in smooth muscle cell migration after arterial injury
77. Migration of arterial wall cells. Expression of plasminogen activators and inhibitors in injured rat arteries
78. Smooth muscle cell migration and matrix metalloproteinase expression after arterial injury in the rat
79. Matrix metalloproteinase of vascular cells are increased in balloon-injured rat carotid artery
80. Plasminogen activator inhibitor type 1 and tissue inhibitor of metalloproteinases-2 increase after atrial injury in rats
81. Regulation of vascular smooth muscle cell migration and proliferation in vitro and in injured rat arteries by a synthetic matrix metalloproteinase inhibitor
82. Overexpression of tissue inhibitor of matrix metalloproteinase-1 inhibits vascular smooth muscle cell functions in vitro and in vivo
83. Adenovirus-mediated gene transfer of the human TIMP-1 gene inhibits smooth muscle cell migration nd neointimal formation in human saphenous vein
84. Primate smooth muscle cell migration from aortic explants is mediated by endogenous platelet-derived growth factor and basic fibroblast growth factor acting through matrix metalloproteinases 2 and 9
85. The role of plasminogen, plasminogen activators, and matrix metalloproteinases in primate arterial smooth muscle cell migration
86. Immunolocalization of matrix metalloproteinases in rabbit carotid arteries after balloon denudation
87. Impaired arterial neointima formation in mice with disruption of the plasminogen gene
88. Urokinase-type but not tissue-type plasminogen activator mediates arterial neointima formation in mice
89. Plasminogen is not required for neointima formation in the mouse model of vein graft stenosis
90. Temporal and topographic matrix metalloproteinase expression after vascular injury in mice
91. Expression of matrix metalloproteinases during rat skin wound healing: Evidence that membrane type-1 matrix metalloproteinase is a stromal activator of progelatinase A
92. Expression of three membrane-type matrix metalloproteinases (MT-MMPs) in rat vascular smooth muscle cells and characterization of MT3-MMPs with and without transmembrane domain
93. Expression of matrix metalloproteinases and their inhibitor TIMP-1 in the rat carotid artery after balloon injury
94. Tissue inhibitor type 1 of matrix metalloproteinases (TIMP-1) impairs arterial neointima formation after vascular injury in mice
95. Antisense oligonucleotides to stromelysin mRNA inhibit injury-induced proliferation of arterial smooth muscle cells
96. Transplant coronary artery disease: Histopathologic correlations with angiographic morphology
97. Proteinases in cardiovascular aneurysms and rupture: Targets for therapy?
98. Basic science of abdominal aortic aneurysms: Emerging therapeutic strategies for an unresolved clinical problem
99. Postinfarction ventricular septal rupture: The Wessex experience
100. Possible key role of plasmin in the pathogenesis of abdominal aortic aneurysms
101. Abnormal expression of plasminogen activators in aortic aneurysmal and occlusive disease
102. Metalloproteinases in degenerative aortic disease
103. Identification and matrix metalloproteinases 3 (stromelysin-1) and 9 (gelatinase B) in abdominal aortic aneurysm
104. Production and localization of 92-kilodalton gelatinase in abdominal aortic aneurysms: An elastolytic metalloproteinase expressed by aneurysm-infiltrating macrophages
105. In situ localization and quantification of mRNA for 92-kD type IV collagenase and its inhibitor in aneurysmal, occlusive, and normal aorta
106. Cellular localization of matrix metalloproteinases in the abdominal aortic aneurysm wall
107. Expression and localization of macrophage elastase (matrix metalloproteinase-12) in abdominal aortic aneurysms
108. Prevention of aneurysm development and rupture by local overexpression of plasminogen activator inhibitor-1
109. MMP inhibition in abdominal aortic aneurysms. Rationale for a prospective randomized clinical trial
110. Targeted gene disruption of matrix metalloproteinase-9 (gelatinase B) suppresses development of experimental abdominal aortic aneurysms
111. Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure
112. Frequency of rupture of the left ventricular free wall or ventricular septum among necropsy cases of fatal acute myocardial infarction since introduction of coronary care units
113. Subacute left ventricular free-wall rupture in early course of acute myocardial infarction. Clinical report of two cases and review of the literature
114. Urokinase plasminogen activator activity is increased in the myocardium during coronary artery occlusion
115. Matrix metalloproteinase inhibition attenuates early left ventricular enlargement after experimental myocardial infarction in mice
116. Regulation of collagen degradation in the rat myocardium after infarction
117. Increased matrix metalloproteinase activity and selective upregulation on in LV myocardium from patients with end-stage dilated cardiomyopathy
118. Myocardial matrix metalloproteinase activity and abundance with congestive heart failure
119. Differential regulation of matrix metalloproteinases associated with aging and hypertension in the rat heart
120. Temporal expression of extra-cellular matrix metalloproteinases and tissue plasminogen activator in the development of collateral vessels in the canine model of coronary occlusion
121. Matrix metalloproteinase inhibition with congestive heart failure improves left ventricular geometry and pump function
122. Matrix metalloproteinase inhibition blocks progression of heart failure